论文部分内容阅读
目的评价卡维地洛治疗原发性轻中度高血压的有效性和安全性。方法194名原发性轻、中度高血压患者入组本研究,随机接受卡维地洛或美托洛尔治疗。卡维地洛组起始剂量为10 mg,2次/d,美托洛尔组起始剂量为25 mg,2次/d,2周后根据舒张压情况调整药物剂量。治疗期间为8周,每2周随访1次,观察疗效和不良事件。结果两组药物治疗两周后血压开始明显下降(P<0.01),卡维地络组比美托洛尔组更显著(P<0.05)。卡维地洛治疗8周后收缩压、舒张压和心率下降分别为[(18.5±15.2)(、13.5±7.9)mm Hg,P<0.01]及(5.9±13.1)次/min(P<0.01),降压总有效率达80.4%;与美托洛尔相比血压、心率降幅均无显著性差异(P>0.05);与基线相比血脂、血糖及其他生化指标均无显著变化;无严重不良事件发生。结论卡维地洛用于原发性轻中度高血压疗效显著,不良反应轻微,耐受性较好。
Objective To evaluate the efficacy and safety of carvedilol in the treatment of essential mild to moderate hypertension. METHODS: One hundred and ninety-four patients with primary mild to moderate hypertension were randomized to receive either carvedilol or metoprolol. Carvedilol group initial dose of 10 mg, 2 times / d, metoprolol group initial dose of 25 mg, 2 times / d, 2 weeks after the adjustment according to diastolic pressure medication dose. During the treatment period of 8 weeks, followed up every 2 weeks to observe the efficacy and adverse events. Results After two weeks of treatment, the blood pressure began to decrease significantly (P <0.01). Carvedilol group was more significant than metoprolol group (P <0.05). After 8 weeks of carvedilol treatment, systolic blood pressure, diastolic blood pressure and heart rate decreased to (18.5 ± 15.2) (13.5 ± 7.9) mm Hg, P <0.01 and 5.9 ± 13.1 times / min, respectively ), The total effective rate of antihypertensive was 80.4%. There were no significant differences in blood pressure and heart rate (P> 0.05) compared with metoprolol. There was no significant change of blood lipid, blood glucose and other biochemical indexes compared with baseline; Serious adverse events occurred. Conclusion Carvedilol is effective in treating primary mild to moderate hypertension with mild adverse reactions and good tolerability.